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Aim: In the present work, the potential of the D-enantiomeric dendrimers dG3KL and dTNS18 
was evaluated in relation to tobramycin (Tob), for the development of novel antibacterials to 
treat Pseudomonas aeruginosa chronic lung infections in patients with cystic fibrosis.
Results: The activity of dendrimers against planktonic P. aeruginosa cells was less than Tob 
against three of the four strains tested (median minimum inhibitory concentration [MIC] 8 vs 
1 µg/mL, respectively), but 32-fold higher against the PaPh32 strain isolated at posttransplan-
tation stage. Results from comparative minimum bactericidal concentration/MIC evaluation 
and time–kill assay suggested a bactericidal mechanism for all test agents. Subinhibitory 
concentrations of both dendrimers and Tob significantly affected biofilm formation by all 
strains in a dose-dependent manner, although the PaPh26 strain, isolated during the chronic 
stage of infection, was particularly susceptible to dendrimers. The activity of dendrimers 
against preformed P. aeruginosa biofilm was generally comparable to Tob, considering 
both dispersion and viability of biofilm. Particularly, exposure to the test agent at 10 × MIC 
caused significant biofilm death (>90%, even to eradication), though with strain-specific dif-
ferences. Single administration of dendrimers or Tob at 10 × MIC was not toxic in Galleria 
mellonella wax-moth larvae over 96 hours. However, contrarily to Tob, dendrimers were not 
protective against systemic infection caused by P. aeruginosa in G. mellonella. Kinetics of 
P. aeruginosa growth in hemolymph showed that bacterial load increased over time in the 
presence of dendrimers.
Conclusion: Overall, our findings indicated that dG3KL and dTNS18 peptide dendrimers show 
in vitro activity comparable to Tob against both P. aeruginosa planktonic and biofilm cells at 
concentrations not toxic in vivo. Further studies are warranted to explore different dosages and 
to increase the bioavailability of the peptides to solve the lack of protective effect observed in 
G. mellonella larvae.
Keywords: cystic fibrosis, chronic infection, Pseudomonas aeruginosa, dendrimer peptides, 
biofilm
Introduction
CF patients are prone to chronic infection of the respiratory tract, which ultimately 
leads to pulmonary failure, the primary cause of death in this patient population.1 
Pseudomonas aeruginosa is the most prevalent respiratory pathogen in adult CF 
patients, where it is the main cause of morbidity and mortality.2
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Whereas P. aeruginosa eradication cannot be achieved 
once the infection is fully established in a CF patient, the aim 
of antimicrobial therapy is a reduction in bacterial density in 
the respiratory tract.3 In the absence of exacerbation, main-
tenance treatment with inhaled antibiotics is used, due to the 
high concentrations reached at the site of infection and the 
minimal systemic effects. Despite the demonstrated efficacy 
of regimes based on cycles of nebulized Tob in reduction of 
bacterial loads, decreasing antibiotic effects are observed over 
time.4 This unfortunate outcome may be explained not only 
by the extraordinary capacity of P. aeruginosa to develop 
resistance through chromosomal mutations5 but also by its 
high ability to adapt to the CF pulmonary environment by 
the formation of biofilms, cellular aggregations embedded 
in extracellular polymeric substances inherently resistant 
to antibiotic therapy, and host immunity.6 This scenario is 
further complicated by evidence that at the site of infection, 
pathogens grow in highly viscous sputum whose composi-
tion (eg, extracellular DNA, lipids, proteins) affects both 
delivery and functionality of  antibiotics.7 As such, adequate 
treatment options are limited and new compounds with potent 
antibiofilm activity are needed urgently.
The potential of using AMPs as a valid alternative to 
conventional antibiotics has been recently recognized and 
studied.8,9 In fact, their generally fast and strong antimi-
crobial activity also directed toward multidrug-resistant 
microorganisms, together with antibiofilm activity and the 
evidence that they are less prone to induce development of 
resistance compared to conventional antibiotics, make AMPs 
lead compounds for anti-infective agent development.10–14
Dendrimers are hyperbranched polymeric molecules with 
an almost-perfect geometrical three-dimensional architecture 
that confers them functionality completely different from 
linear polymers.15 The potential of using dendrimers as 
antimicrobial agents has been recognized over the last 10–15 
years. Although they can use different mechanisms of action, 
generally associated with the multivalence of the branched 
scaffold, they typically cause increased membrane perme-
ability and consequent bacterial lysis following electrostatic 
interactions with the negatively charged bacterial membrane 
of both Gram-positive and Gram-negative bacteria.16,17
In this context, two very interesting dendrimers have been 
recently obtained: G3KL, a third-generation dendrimer con-
sisting of 37 amino acids, whose structure contains dipeptides 
(lysine and leucine) coupled via lysine residue, which proved 
to be active also against carbapenemase-producing P. aerugi-
nosa and Acinetobacter baumannii clinical strains;18,19 and the 
second-generation dendrimer TNS18, consisting of 18 amino 
acids with the presence of a lipid, similarly to polymyxin’s 
structure, displaying a broader antibacterial activity spectrum 
compared with G3KL, since it also includes MRSA.20 Despite 
their activity against MDR clinical strains, both dendrimers 
show lower stability than d-enantiomeric dendrimers in the 
presence of serum.19,20
The aim of the present study was to evaluate for the first 
time the potential of the metabolically more stable d-enan-
tiomeric dendrimers dG3KL and dTNS18 as compounds 
for the development of novel antibacterials to treat lung 
infections caused by P. aeruginosa in patients affected by CF. 
Four P. aeruginosa strains, representative of different stages 
of CF infection, were selected to assess both dendrimers 
for in vitro activity against planktonic and biofilm cells, as 
well as in vivo toxic potential and protective effects against 
P. aeruginosa systemic infection in the Galleria mellonella 
invertebrate.
Methods
Bacterial strains and growth conditions
The four P. aeruginosa strains tested in the present study 
were isolated from sputum samples collected by CF patients 
at different stages of infection: PaPh13 and PaPh14 at the 
early stage, PaPh26 at the chronic stage, and PaPh32 at the 
posttransplantation stage. PaPh32 was the only strain showing 
a mucoid phenotype. All strains were stored at –80°C in a 
Microbank system (Pro-Lab Diagnostics, Toronto, Canada) 
until use, when they were aerobically grown at 37°C in 
TSB (Thermo Fisher Scientific, Waltham, MA, USA), and 
then twice on MHA (Thermo Fisher Scientific) to check for 
contamination and regain the original phenotype. All assays 
were carried out using a standardized bacterial inoculum. 
Briefly, P. aeruginosa colonies grown overnight on MHA 
were resuspended in TSB and incubated for 16 hours at 
37°C under agitation (150 rpm). Suspension was adjusted 
to an OD
550
 of 1 (corresponding to 1–5×108 CFU/mL) and 
then diluted 1:10 in TSB. Inoculum size was confirmed by 
cell-viability count on each experiment.
Peptide dendrimers
The chemical structure and characteristics of dG3KL and 
dTNS18 peptide dendrimers are summarized in Figure 1. 
Synthesis was performed at the Department of Chemistry 
and Biochemistry, University of Berne with a CEM Liberty 
Blue automated microwave synthesizer under solid-phase 
peptide-synthesis conditions at 0.25 mmol using Rink amide 
SpheriTide (0.19 mmol/g) resin. The resin was swollen in 
DCM–DMF 1:1 mixture and transferred to a reaction vessel 
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Figure 1 Peptide dendrimers dG3KL and dTNS18 tested in the present study.
Notes: (A) Chemical structure. (B) Physicochemical properties. C-termini are carboxamide CONH2. 
aOne-letter codes for amino acids (l, leucine; k, lysine; o, ornithine; b, 
diaminobutyric acid; k, branching lysine and K [C10], side-chain decanoylated lysine).
Abbreviation: MS, mass spectrometry (to assess molecular weight).
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A
B
from an HT loader. Deprotection was performed with 20% 
(v:v) piperidine in DMF for 2 minutes at room temperature 
and 3 minutes at 75°C. Unprotected amino groups of resin 
or amino acids were acylated with 3 mL 0.2 M amino acid 
solution in DMF, 2 mL 1.0 M DIC in DMF, and 2 mL 1.0 
M Oxyma Pure (ethyl cyanohydroxyiminoacetate) in DMF 
for 5 minutes at 75°C. Synthesis was programmed for one 
deprotection and one coupling (G
0
), one deprotection and 
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two couplings (G
1
), one deprotection and four couplings 
(G
2
), and two deprotections and eight couplings (G
3
).
A lipid chain was attached to the dTNS18 with modifica-
tions. Fluorenylmethyloxycarbonyl (Fmoc)-d-Lys(Alloc)-
OH was attached first to the resin. Before deprotection of the 
last Fmoc-group, the Alloc protecting group was removed 
under dry conditions with 0.25 eq Pd(PPh
3
)
4
 and 25 eq 
PhSiH
3
 in 10 mL dry DCM. This step was repeated twice 
with washing of the resin with twice-dried DCM in between. 
After the second cycle, the resin was washed for 1 hour twice 
with DCM and the lipid chain attached to dendrimer with 
carboxylic acid (5 eq/amine), Oxyma Pure (5 eq/amine), and 
DIC (5 eq/amine) in N-methyl-2-pyrrolidone and stirred once 
overnight and once for 2 hours at room temperature.
Final deprotection was done in 20% piperidine in DMF 
(2×10 minutes) manually after the synthesis. The resin was 
washed twice with MeOH and dried under vacuum before 
cleavage was carried out using TFA–triisopropylsilane–H
2
O 
(94:5:1 v:v:v) over 4.5 hours. After filtration, the peptide 
was precipitated with 50 mL ice cold TBME, centrifuged at 
4,400 rpm for 15 minutes, and washed twice with TBME. For 
purification, the crude peptide was subjected to preparative 
RP-HPLC. Elution solutions were Milli-Q deionized water 
containing 0.1% TFA, Milli-Q deionized water–acetonitrile 
(10:90 v:v) containing 0.1% TFA, and purified compound 
obtained as TFA salt after lyophilization.
Tob
Tob as powder with known potency was from Sigma-Aldrich 
Co. (St Louis, MO, USA). For each test agent, a stock solu-
tion was prepared at 10 mg/mL in Milli-Q reagent water, 0.22 
µm-filtered, and finally stored at −80°C until use.
MIC and MBC measurement
The lowest concentration of the test agent that completely 
inhibited visible bacterial growth (MIC) was determined 
in CAMHB (BD, Franklin Lakes, NJ, USA) by microdilu-
tion according to Clinical Laboratory Standards Institute 
guidelines.21 P. aeruginosa ATCC 27853 was chosen as the 
quality-control strain in each batch of tests. Following MIC 
reading, the lowest concentration of the test agent killing at 
least 99.99% of the original inoculum (MBC) was measured 
by plating 100 µL broth from clear wells on MHA plates and 
incubation at 37°C for 24 hours for CFU count.22
Time–kill assay
Kinetics of both peptide dendrimers and Tob activity against 
P. aeruginosa was evaluated by broth macrodilution. Briefly, 
the standardized inoculum (1–2×106 CFU/mL) was exposed 
to the test agent at MIC in CAMHB and incubated at 37°C in a 
spectrophotometric reader (SpectraMax Plus 384; Molecular 
Devices LLC, Sunnyvale, CA, USA). OD
550
 readings were 
performed every 15 minutes up to 24 hours, when a viable-
cell count was performed by seeding the entire content of 
the wells where no growth was recorded.
Screening for biofilm formation
Each P. aeruginosa strain was evaluated for the ability to form 
biofilm over 48 hours using a microtiter-plate method. Briefly, 
200 µL standardized inoculum was aliquoted in each well of 
a 96-well polystyrene, flat-bottomed, tissue-culture-treated 
microtiter (Kartell, Milan, Italy) and statically incubated 
at 37°C. Following 24 and 48 hours’ incubation, biofilm 
samples were washed twice with PBS (EuroClone, Pero, 
Italy), scraped with a pipette tip following 5 minutes’ expo-
sure to 100 µL trypsin-EDTA 0.25% (Sigma-Aldrich), and 
then underwent tenfold dilutions for colony count onto MHA.
In vitro activity against biofilm formation
In each well of a 96-well flat-bottomed polystyrene microti-
ter plate, 5 µL standardized inoculum was added to 100 µL 
CAMHB containing test agent at concentrations equal to 
1/2×, 1/4×, and 1/8× MIC. After incubation at 37°C for 24 
hours, nonadherent bacteria were removed by washing twice 
with 100 µL sterile PBS (pH 7.2). Slime and adherent cells 
were fixed by incubation for 1 hour at 60°C and stained 
for 5 minutes at room temperature with 100 µL 1% crystal 
violet solution (Sigma-Aldrich). Wells were then rinsed with 
distilled water and dried at 37°C for 30 minutes. Biofilms 
were destained by treatment with 100 µL 33% glacial acetic 
acid (Sigma-Aldrich) for 15 minutes and OD
492
 measured 
(Sunrise; Tecan, Männedorf, Switzerland). The low cutoff 
was represented by approximately three SDs above the mean 
OD
492
 of control wells (containing medium alone without 
bacteria). The percentage of inhibition was calculated as 
(1 – OD
492
 of test/OD
492
 of untreated control) ×100.23
In vitro activity against preformed biofilm
Biofilm was allowed to grow for 24 hours in each well of a 
96-well microtiter plate, as described in the “Screening for 
biofilm formation” section. Next, biofilm was exposed to 
each test agent at concentrations of 1–16× MIC and prepared 
in CAMHB. Following 24-hour exposure at 37°C, the effect 
against mature biofilm was evaluated both by crystal violet 
(dispersion of biofilm biomass) and colony count (biofilm 
viability) assays.
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In vivo toxicity assay
The toxicity of dendrimers and Tob was comparatively 
assessed in G. mellonella wax-moth larvae.24 For each 
group, 20 larvae weighing 250–350 mg were injected using a 
 Hamilton syringe (Sigma-Aldrich) directly into the hemocoel 
via the left proleg with 10 µL test agent at a concentration of 
10 × MIC in distilled H
2
O. Control larvae were inoculated with 
distilled water only. Larvae were incubated at 37°C, and the 
number of dead caterpillars was counted every 24 hours until 
96 hours, considering as dead those unresponsive to touch.24
In vivo protection studies
Firstly, an inoculum test was performed to determine the 
optimum inoculum for staggered larval killing (ie, LD
50
 at 
24 hours postinoculation). G. mellonella larvae (n=20/group) 
were infected with several infectious doses (102, 103, 104, 
105, and 106 CFU/larvae) via a 10 µL injection into the left 
proleg, then incubated at 37°C and scored for survival at 24, 
48, 72, and 96 hours. Control larvae were administrated with 
vehicle (PBS) only.
Next, in the protection studies, larvae (n=20/group) 
were infected with P. aeruginosa strains, each at relative 
LD
50
 (5×105 CFU/larva and 104 CFU/larva, respectively, for 
PaPh26 and PaPh32 strains; 10 CFU/larva both for PaPh13 
and PaPh14 strains). After 30 minutes, a second injection 
into the hemocoel via the right proleg of dendrimer or Tob 
was administered, each at 10 × MIC. Control larvae were 
infected, but exposed to H
2
O only. Larvae were incubated 
at 37°C and scored for survival at 24, 48, 72, and 96 hours.
Kinetics of bacterial growth in 
hemolymph
G. mellonella larvae were infected with P. aeruginosa and 30 
minutes later administered dendrimer or Tob at 10 × MIC, 
as previously described. At 4 and 12 hours posttreatment, 
G. mellonella larvae were anesthetized by placing them in 
ice for 5 minutes until no leg movement could be observed, 
and then, hemolymph was collected following incision 
between two segments near the head. Quantification of P. 
aeruginosa within pooled hemolymph samples from five 
larvae was done by preparing serial dilutions and enumerat-
ing by total viable count onto cetrimide agar (Thermo Fisher 
Scientific). Saturated thiourea was added to hemolymph to 
prevent melanization.
Statistical analysis
All experiments were performed at least in triplicate and 
repeated on at least two occasions. Differences between MIC 
or MBC values were considered significant for discrepancies 
>1-log
2
 concentration steps. Statistical significance of dif-
ferences was evaluated using ANOVA followed by Tukey’s 
multiple-comparison test (for normally distributed data), 
unpaired t-test (kinetics of bacterial growth in hemolymph), 
or by Fisher’s exact test (proportions). Survival curves were 
analyzed using the log-rank (Mantel–Cox) test. Statistical 
analysis of results was conducted with GraphPad Prism 4.00 
(GraphPad Software, Inc., La Jolla, CA, USA), considering 
as statistically significant P<0.05.
Results
Activity against planktonic cells: MIC, 
MBC
Susceptibility-test results are summarized in Table 1. 
 Dendrimers dG3KL and dTNS18 showed comparable activ-
ity (median MIC and MBC 8 µg/mL), except for the PaPh13, 
strain whose MIC and MBC values were significantly (>1 log
2
) 
lower for dTNS18. Tob was significantly more active com-
pared to the tested peptides (median MIC 1 µg/mL), although 
strain-dependent activity was observed. In particular, Tob was 
less active than either dendrimer against PaPh32, showing an 
MIC value ≥32-fold higher than both. MBC values for both 
peptides and Tob were within 1-log
2
 dilution compared to 
respective MIC values, suggesting bactericidal activity for 
all test agents.
Time–kill
The effect of both peptide dendrimers on P. aeruginosa 
growth was assessed comparatively to Tob, monitoring 
bacterial growth over 24 hours following a single exposure 
at MIC (Figure 2). Viable cell counts were performed after 
24 hours’ incubation to check for eradication. Exposure to 
dG3KL allowed regrowth for P. aeruginosa PaPh14 and 
PaPh32 strains only, after 21 and 11 hours’ incubation, 
respectively. Bacterial counts performed after 24 hours’ 
Table 1 In vitro antibacterial activity of dendrimer peptides 
compared to Tob against Pseudomonas aeruginosa strains from CF 
patients
Strain dG3KL dTNS18 Tob
MIC MBC MIC MBC MIC MBC
PaPh13 128 128 16 16 1 2
PaPh14 8 8 8 8 1 1
PaPh26 8 16 8 8 8 16
PaPh32 8 8 8 8 >128 >128
Notes: Values expressed as µg/mL.
Abbreviations: MIC, minimum inhibitory concentration; MBC, minimum 
bactericidal concentration; Tob, tobramycin; CF, cystic fibrosis.
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Figure 2 Time–kill kinetics of dendrimers and Tob against Pseudomonas aeruginosa.
Notes: A standardized inoculum (1–2×106 CFU/mL) of each P. aeruginosa strain (PaPh13, PaPh14, PaPh26, and PaPh32) was exposed to each peptide or Tob at MIC value. 
OD550 was measured every 15 minutes over 24 hours. Each experiment was carried out in triplicate and repeated twice. In the case of PaPh32, Tob was not tested because 
of out-of-range MIC (>128 µg/mL).
Abbreviations: MIC, minimum inhibitory concentration; Tob, tobramycin.
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incubation showed eradication of PaPh13, but the presence 
of PaPh26 in low numbers (<350 CFU/mL). In contrast, no 
growth was observed following dTNS18 exposure, regard-
less of the strain considered. Cell-viability counts performed 
following 24 hours’ incubation confirmed the eradication of 
PaPh14 and PaPh32 strains, whereas PaPh13 and PaPh26 
were found to be present, although at very low concentrations 
(<50 CFU/mL). Tob caused a delay in bacterial growth of 13 
and 8 hours for PaPh13 and PaPh14 strains, respectively. No 
growth was observed over 24 hours for PaPh26, although a 
bacterial load of 3.5×102 CFU/mL was achieved.
Screening for biofilm formation
Kinetics of biofilm formation onto polystyrene by P. aerugi-
nosa strains were evaluated by viable cell count, and results 
are summarized in Figure 3. All strains produced biofilm 
throughout 48 hours, although the cellularity of PaPh14 
was significantly higher than other strains, regardless of the 
incubation time considered (4.7+2.9×107 and 2.5+1.6×107 
CFU/well, respectively, for 24 and 48 hours; P<0.01 vs other 
strains). Since the cellularity of biofilm did not change sig-
nificantly over 48 hours, to evaluate the activity of peptides 
on mature biofilm, a biofilm preformed for 24 hours was 
exposed to each peptide for a further 24 hours.
Effect of subinhibitory concentrations 
against biofilm formation
To evaluate the effect of peptides in preventing biofilm forma-
tion by P. aeruginosa, subinhibitory concentrations of each 
peptide were tested against biofilm formation, and results are 
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shown in Figure 4. Considering the proportion of cases where 
biofilm formation was significantly reduced in the presence 
of the test agent, comparable activity was observed for both 
dendrimers and Tob, with 50% (six of 12 cases) for dTNS18, 
41.6% (five of 12) for dG3KL, and 33% (four of 12) for Tob. 
Reductions were significantly higher in the presence of 1/2 
× MIC (75% vs 25% and 25%, respectively, for 1/2 ×, 1/4 ×, 
and 1/8 × MIC; P<0.05), thus indicating a dose-dependent 
antibiofilm effect. Particularly susceptible to the effect of 
dendrimers was PaPh26, isolated during the chronic stage of 
infection, whose biofilm formation was affected regardless 
of the concentration tested. Although in a minor number of 
cases, exposure to peptides at sub-MIC caused a significant 
increase in biofilm-biomass formation compared to untreated 
control samples. This effect was not dependent on dose or 
strain considered.
Biofilm dispersion caused by inhibitory 
concentrations
The effect of peptides at MIC and its multiples on the dis-
persion of preformed biofilm by P. aeruginosa was assessed 
comparatively to Tob, and results are shown in Figure 5. 
Considering the number of cases where preformed biofilm 
was dispersed significantly following treatment, Tob caused 
more of reductions compared to dendrimers, although dif-
ferences were not statistically significant (60% vs 35% and 
35%, respectively). The effect was not dependent on the 
concentration tested. In contrast, strain-dependent activity 
Figure 3 Screening for biofilm formation by Pseudomonas aeruginosa.
Notes: Biofilm was allowed to form in 96-well microtiter in trypticase soy broth 
for 24 and 48 hours. Biofilm cellularity was evaluated by viable cell counts. Each 
experiment was carried out in triplicate and repeated three times, and results are 
shown as mean + SD. No statistically significant differences were observed between 
24 hours and 48 hours by unpaired t-test. **P<0.01, ***P<0.001 vs other strains; 
ANOVA + Tukey’s multiple comparison posttest.
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Figure 4 Effect of dendrimers and Tob on Pseudomonas aeruginosa-biofilm formation.
Notes: Biofilms were allowed to form (37°C, 24 hours) in each well of a 96-
well microtiter plate in the presence of each peptide tested at several sub-MIC 
levels (1/2×, 1/4×, and 1/8×). Biofilm biomass was then measured by crystal violet 
assay. Effect against biofilm formation shown as variation in percentage of biofilm 
biomass measured after exposure compared to control (exposed to vehicle only). 
Each experiment was carried out in triplicate and repeated twice, and results are 
shown as mean + SD. Dotted lines show statistically significant variations (>±30% vs 
control; P<0.05, Fisher’s exact test) in biofilm formation.
Abbreviations: MIC, minimum inhibitory concentration; Tob, tobramycin.
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Increases were comparable for all molecules (35% vs 30% 
vs 26.7%, respectively, for dTNS18, dG3KL, and Tob). The 
effect was not dependent on both concentration or strain 
tested.
Effect against viability of preformed 
biofilm
The effect of peptides at bactericidal concentration (10 × 
MIC) on the viability of preformed biofilm by P. aeruginosa 
was evaluated comparatively to Tob using viable cell counts, 
and results are shown in Figure 6. Exposure to Tob always 
caused a significant reduction in biofilm viability compared 
to unexposed controls (killing ≥99.96%). This effect was 
generally comparable to that provoked by peptides (killing 
range 90.2%–100% and 90.6%–100%, respectively, for 
dG3KL and dTNS18), with the exception of PaPh14, whose 
biofilm cellularity was not affected by exposure to peptides 
compared to unexposed controls, but decreased significantly 
following treatment with Tob (1.6±0.1×107 vs 1.4±0.5×107 vs 
1.4±0.2×103 CFU/well, respectively, for dG3KL, dTNS18, 
and Tob; P<0.001).
In vivo toxicity
To assess the toxic potential associated to the bactericidal dose 
used in biofilm assays, G. mellonella larvae were administered 
10 × MIC of each peptide and Tob and a survival curve plotted, 
as shown in Figure 7. Overall, no significant differences were 
observed in the survival rate of peptide- or Tob-administrated 
larvae by log-rank (Mantel–Cox) test. In particular, on day 1 
PE, both peptides caused the same mortality rate observed in 
control unexposed larvae (two of 40 larvae, 5%). The same 
mortality rate was observed in Tob-exposed larvae on day 2 
PE, where dG3KL and dTNS18 provoked death in 15% and 
10% of the larvae population. On day 3 PE, the mortality rate 
associated with Tob increased to 10%. No death was observed 
on day 4 PE.
In vivo infection assays
To determine whether G. mellonella larvae were a suitable 
model to study the protective effect of peptide dendrimers 
against P. aeruginosa infection, we first defined its infection 
characteristics. The effect of infection with P. aeruginosa 
PaPh13, PaPh14, PaPh26, and PaPh32 on G. mellonella lar-
vae survival is shown in Figure 8. Overall, our results show 
that G. mellonella was susceptible to P. aeruginosa infection. 
Particularly, P. aeruginosa PaPh13 and PaPh14 were the most 
virulent strains, causing killing ≥97.5% within 24 hours, 
regardless of dose administered. In contrast, the killing rate 
Figure 5 Pseudomonas aeruginosa-biofilm dispersion caused by dendrimers and Tob.
Notes: Biofilm was allowed to form in a 96-well microtiter plate at 37°C for 24 hours, 
and then exposed for a further 24 hours to each peptide (dG3KL, dTNS18) or Tob at 
MIC and multiple MIC (2×, 4×, 8×, and 16×). Tob was not tested against PaPh32 strain 
because of out-of-range MIC (>128 µg/mL). Effect against preformed biofilm shown 
as variation in percentage of biofilm biomass measured after exposure compared to 
control (exposed to vehicle only). Each experiment was carried out in triplicate and 
repeated twice, and results are shown as mean + SD. Dotted lines show statistically 
significant variations compared to control (>±30% vs control; P<0.05, Fisher’s exact test).
Abbreviations: MIC, minimum inhibitory concentration; Tob, tobramycin.
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was observed for both Tob (PaPh13 and PaPh26) and dG3KL 
(PaPh13). In a comparable number of cases, the exposure 
to Tob or peptides caused a significant increase of biofilm 
biomass formation compared to untreated control samples. 
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Figure 6 In vitro activity of peptides and Tob against viability of preformed biofilm by Pseudomonas aeruginosa.
Notes: Biofilm was allowed to form in a 96-well microtiter plate at 37°C for 24 hours, and then exposed for a further 24 hours to each peptide (dG3KL, dTNS18), or Tob at 
10 × MIC. Control biofilm was exposed to vehicle only (control). Results expressed as mean + SD (left) and proportion of dead and live cells after exposure (right). **P<0.01, 
***P<0.001, ****P<0.0001 vs control; P<0.01, P<0.001 vs Tob; ANOVA + Tukey’s multiple comparison post-test.
Abbreviations: MIC, minimum inhibitory concentration; Tob, tobramycin.
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Figure 7 In vivo toxicity assays.
Notes: Galleria mellonella larvae (n=20/group) were administered by intra-hemocoel injection with peptides (dG3KL and dTNS18) or Tob, each at doses equal to 10 × 
MIC (corresponding to 80, 160, and 80 µg/larva, respectively). Survival of larvae was monitored daily over 96 hours. Results shown as mean values from two independent 
determinations (n=20 each). No significant differences between curves found by Log-rank (Mantel–Cox) test.
Abbreviations: MIC, minimum inhibitory concentration; Tob, tobramycin.
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Figure 8 In vivo Pseudomonas aeruginosa-killing assays.
Notes: Galleria mellonella larvae (n=20/group) were infected with different doses (10, 102, 103, 104, 105, and 106 cells) of PaPh13, PaPh14, PaPh26, and PaPh32 strains. Survival was 
then monitored daily over 96 hours. Results shown as mean + SD from two independent experiments (n=20 each). Control larvae administered PBS only. Dotted lines, LD50.
Abbreviation: LD50, lethal dose 50.
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was significantly dependent on the number of cells injected 
in a dose-dependent manner for P. aeruginosa PaPh26 and 
PaPh32. PaPh32 caused a death rate ≥95% when tested at 
doses of 106 and 105 CFU/larva, whereas a comparable killing 
rate was achieved by PaPh26 only at 106 CFU/larva. Based 
on these results, we chose the infectious doses to be used 
in protective studies: 10 CFU/larva (PaPh13 and PaPh14), 
5×105 CFU/larva (PaPh26), and 104 CFU/larva (PaPh32).
In vivo protective studies
The protective effect of peptides against P. aeruginosa infec-
tion was evaluated comparatively to Tob in G. mellonella by 
monitoring survival over 96 hours following administration 
of each molecule at 10 × MIC (Figure 9). Treatment with pep-
tides provided no protection against P. aeruginosa infection, 
as indicated by mortality rates comparable with the positive 
control (infected but not treated). In contrast, treatment with 
Tob allowed significant protection against P. aeruginosa 
infection compared to untreated larvae, regardless of the 
strain tested (P<0.01, P<0.001, and P<0.0001, respectively, 
for PaPh13, PaPh14, and PaPh26 vs controls).
Kinetics of bacterial growth in 
hemolymph
The antibacterial activity of dendrimers was assessed over 
12 hours compared to Tob in pooled hemolymph from 
G. mellonella larvae infected with PaPh14 and PaPh26, 
selected on the basis of their different virulence, as previ-
ously described in the “In vivo infection assays” section 
(Figure 10). Overall, bacterial load increased over time in 
the presence of dendrimers, regardless of the strain tested. 
A similar trend was observed for Tob, except for PaPh26, 
where a decrease was observed. The kinetics of bacterial 
killing were strain-dependent.
Figure 9 In vivo protection against systemic Pseudomonas aeruginosa (Pa) infection.
Notes: Galleria mellonella larvae (n=20/group) were infected by injection of the selected infectious dose of Pa. After 30 minutes, larvae were treated with peptides (dG3KL, 
dTNS18) or Tob at 10 × MIC. Control larvae were infected and then exposed to vehicle only (Pa + H2O). Negative control consisted of uninfected and untreated larvae (PBS 
+ H2O). Survival was monitored daily over 96 hours. Results shown as percentage survival from two experiments (n=20 each). **P<0.01, ***P<0.001, ****P<0.0001 vs positive 
control; Log-rank (Mantel–Cox) test. Tob not tested against PaPh32 strain because of out-of-range MIC value (>128 µg/mL). Dotted lines, LD50.
Abbreviations: MIC, minimum inhibitory concentration; Tob, tobramycin; LD50, lethal dose 50.
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No significant differences were observed between treated 
and control groups in larvae infected by PaPh14. Conversely, 
when larvae were infected with PaPh26, the bacterial load 
measured at 4 hours posttreatment in control larvae was signifi-
cantly higher than in treated larvae, regardless of the molecules 
considered (1.5±0.01×104 vs 3.4±0.1×103, 2.6±0.2×103, and 
1.9±0.1×103 CFU/larva, respectively for untreated, dG3KL-
treated, dTNS18-treated, and Tob-treated larvae; P<0.0001). 
Further, P. aeruginosa concentration in dG3KL-infected larvae 
was significantly higher compared with dTNS18 (P<0.05) 
and Tob (P<0.01). Following 12 hours, the bacterial load was 
reduced after exposure to Tob compared to untreated larvae, 
although not to a statistically significant extent.
Discussion
Representing the defense system of multicellular organ-
isms,25–27 AMPs offer an interesting alternative to antibiotic 
therapy in addressing antibiotic-resistant strains, especially 
in CF patients, where increasing incidence of MDR P. aeru-
ginosa strains poses significant challenges for clinicians.28 
These peptides typically contain up to 50 amino acids with 
many basic residues (lysine or arginine) and at least 30% 
hydrophobic side chains29 and act mostly by folding into 
amphipathic conformations, inducing membrane disruption, 
similarly to various peptidomimetic systems.30–32
Amino-acid-sequence variations in linear and cyclic 
AMPs have been explored widely, although alternative 
 topologies of the peptide chain have not been studied exten-
sively for AMP design. Dendrimer topology has only been 
used as a tool to achieve multivalence of preexisting AMP 
sequences or single amino acids, typically by attachment to 
a dendritic polylysine tree.33,34 By exploring unusual multi-
branched topologies of the peptide chain, such as peptide 
dendrimers and bicyclic peptides, and extending on previous 
reports that multivalent display of AMPs on a polylysine tree 
can increase their antimicrobial activity,33,34 Stach et al and 
Siriwardena et al recently identified two AMPs, dG3KL and 
dTNS18, with broad antibacterial activity, including MDR 
strains.19,20
dG3KL is a third-generation dendrimer consisting of 
37 amino acids with a lysine–leucine dipeptide repeated 
across the dendrimer branches.19 The leucine residues not 
only enhance the hydrophobicity of G3KL but also enable 
medium-dependent conformational changes, which might 
contribute to the antimicrobial effect.19 dTNS18 is a second-
generation dendrimer of 18 amino acids with the presence of 
a lipid, similar to polymyxin structure.20 Both peptides are 
stable in serum, and their mechanism of action consists in 
the interaction with the negatively charged lipids of the mem-
brane, enabling its disruption with consequent rapid bacterial 
killing. Further, their activity is not affected by the lipopoly-
saccharide layer, an efficient barrier against hydrophobic 
compounds, as indicated by unchanged activity against 
lipopolysaccharide-mutant strains of P. aeruginosa.19,20
In this study, we evaluated (using both in vitro and in vivo 
assays) for the first time the potential of dG3KL and dTNS18 
as compounds for the development of novel antibacterials to 
treat lung infections caused by P. aeruginosa in CF patients. 
With this aim, four P. aeruginosa strains were selected and 
isolated at different stages of CF infection: PaPh13 and 
PaPh14 at the early stage, PaPh26 at the chronic stage, and 
PaPh32, the only one showing a mucoid phenotype, at the 
posttransplantation stage.
First, dendrimers were evaluated comparatively to Tob for 
in vitro activity against planktonic cells of P. aeruginosa CF 
strains. Our results indicated that both dendrimers showed 
comparable activity against most P. aeruginosa strains 
(median MIC 8 µg/mL), although dTNS18 was more effec-
tive against PaPh13, since it was active at a concentration 
3-log
2
 lower than dG3KL. Tob was generally more active 
Figure 10 Kinetics of Pseudomonas aeruginosa (Pa) growth in Galleria mellonella 
hemolymph.
Notes: G. mellonella (n=20/group) was infected by injection of an infectious dose of 
PaPh14 and PaPh26 Pa strains. After 30 minutes, larvae were treated with peptides 
(dG3KL, dTNS18) or Tob at 10 × MIC or vehicle only (H2O; Ctrl). Following 4 and 
12 hours of treatment, hemolymph was collected from each larva, pooled (as groups 
of five larvae), and underwent viable cell counts. Results shown as mean + SD from 
two experiments. *P<0.05; **P<0.01; ***P<0.001; unpaired t-test.
Abbreviations: MIC, minimum inhibitory concentration; Tob, tobramycin.
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than  dendrimers (median MIC 1 µg/mL), although strain-
dependent activity was observed. In the case of PaPh32 – the 
only one showing a mucoid phenotype among strains tested – 
both dendrimers were at last 32-fold more active than Tob, as 
indicated by MIC values. This finding is particularly relevant, 
since P. aeruginosa isolated from CF patients often harbors 
a mucoid phenotype, related to the overproduction of extra-
cellular polysaccharides, among which alginate contributes 
to the chronicity of infections, since it affects the activity of 
several classes of antibiotics.35
MBC values were always within 1-log
2
 dilution compared 
to MIC for both dendrimers and Tob, indicating a probable 
bactericidal mechanism of action at the site of infection. 
Time–kill results confirmed a bactericidal effect particularly 
relevant in the case of dendrimers, which caused significantly 
more delayed regrowth compared to Tob and even eradication. 
Our results are in agreement with Stach et al and Siriwar-
dena et al,19,20 who reported on dG3KL and dTNS18 activity 
against MDR P. aeruginosa strains, although they observed 
a relevant strain-dependent effect, as suggested by the wide 
range in MIC values (4–32 µg/mL).
During chronic colonization, pathogens adapt over time 
to cope with changing selection pressures, coinfecting spe-
cies, and antibiotic therapies.35 In the case of the CF lung, 
these adaptations are induced by environmental pressures, 
such as inflammatory responses, hypoxia,  nutrient deficiency, 
 osmolarity, low pH, and repeated cycles of antibiotic therapy. 
Several studies have clearly shown that the long-term per-
sistence of P. aeruginosa in the airways of CF patients is 
associated with complex and finely tuned mechanisms of 
adaptation.36–40 Among these, a highly successful survival 
strategy of P. aeruginosa, as well as for other CF pathogens,41,42 
involves the production of biofilms, multilayered microbial 
communities adhered to a substratum whose formation is 
finely regulated by a “quorum-sensing” system comprising 
networks of genes and regulators.43 In this state, bacteria are 
surrounded by a dense extracellular polymeric matrix, mainly 
constituted of bacterial polysaccharides, which protects them 
against the inflammatory defense mechanism (mainly phago-
cytosis) and prevents penetration throughout the biofilm of 
antibiotic agents, making them 100- to 1,000-fold more toler-
ant to antimicrobial agents than planktonic counterparts.44,45
Confirming the high ability of P. aeruginosa to adapt to 
the CF lung, all strains tested in the present study were able, 
though with striking differences, to form stable biofilm over 
48 hours using a microtiter plate. The potential of dendrimers 
for prophylactic use in preventing biofilm formation was 
assessed at doses lower than MIC using the crystal violet 
assay to measure biofilm biomass. Comparative evaluation 
of the percentage of cases where exposure to the test agent 
caused a significant reduction in biofilm biomass compared 
to controls indicated that both peptides exhibited activity 
similar to Tob. Antibiofilm activity was dose-dependent, 
with maximum activity observed following exposure to 1/2 
× MIC, and also strain-specific, with chronic PaPh26 the 
most susceptible among those tested.
Exposure to peptides at sub-MIC values also caused a 
significant increase in biofilm-biomass formation compared 
to untreated control samples, although in a minor number of 
cases. As previously observed for some antibiotics46–48 and 
human LL37 and bovine BMAP27 and BMAP28 cathelici-
dins,10,49 biofilm-viability enhancement in the presence of 
subinhibitory concentrations of peptides might be due to the 
upregulation of specific pathways using antimicrobial com-
pounds as activating signals or to the triggering of a bacterial 
stress response inducing the bacteria to develop biofilm as 
a resistance form. These findings highlight once again the 
common need to modulate precisely the amount of antibiotic 
compound to be administered, in order to avoid detrimental 
side effects during antimicrobial therapy.
To assess their therapeutic potential for the treatment of 
chronic biofilm-associated P. aeruginosa infections in the 
CF lung, dG3KL and dTNS18 were also tested at multiples 
of MIC against preformed P. aeruginosa biofilm. At first, 
we evaluated the effect on the dispersal of biofilm biomass, 
consisting of both cells and extracellular matrix, by crystal 
violet assay. Exposure to Tob caused dispersal at a percent-
age higher than dendrimers, although differences were not 
significant. Next, we evaluated cell-viability to assess the 
effect of exposure to 10 × MBC on the viability of preformed 
biofilm. Both dendrimers were effective in reducing the 
viability of preformed biofilms, even until eradication (kill-
ing rate 90.2%–100%), with the exception of PaPh14, whose 
biofilm was intrinsically resistant. In contrast to dendrimers, 
Tob was effective against all strains tested, with a killing 
rate near eradication (≥99.96%). Inherent resistance shown 
by P. aeruginosa PaPh14 biofilm to peptides deserves fur-
ther study to elucidate the underlying mechanisms. We can 
speculate that dendrimer activity could be affected by the 
high cellularity of PaPh14 biofilm, the highest among strains 
tested. Further, excessive amounts of extracellular DNA – an 
important component in P. aeruginosa biofilm50,51 – could 
sequester dendrimers, due to its high affinity with cationic 
AMPs.52
The clinical relevance of the antibiofilm effects exhibited 
in vitro by dendrimers was further investigated by assessing 
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toxic potential associated with bactericidal concentrations 
we used against preformed biofilms. Although cultured cells 
are often used to estimate chemical doses for subsequent 
rodent acute-toxicity tests, this model cannot simulate phar-
macokinetics associated with metabolism of the compound, 
making it poorly predictive. G. mellonella – the greater 
wax moth – has been recently introduced as an alternative 
and highly predictive model to study bacterial diseases, 
antimicrobial drug testing, and acute toxicity of drugs.53–56 
Although this invertebrate does not have lungs, it has been 
frequently used to gain new knowledge in the pathogenesis 
of human lung infections, including those observed in CF 
patients.56,57 Benefits associated with the use of G. mellonella 
over traditional mammalian models (low costs, presence of 
sophisticated cellular and humoral defenses very similar to 
innate immunoresponses of mammals, larvae can be easily 
maintained and infected by injection without anesthesia, not 
subject to ethical limitations of mammalian models, larvae 
can be maintained at 37°C, well suited for study of human 
pathogens) makes this model useful for prescreening evalu-
ation of the efficacy of antimicrobial agents, thus lowering 
the number of test agents proceeding to confirmatory tests 
in rodent models.57 In the present study, we administered 
G. mellonella larvae with 10 × MIC of each peptide and 
compared with Tob, and a survival curve over 4 days was 
plotted. Overall, our results indicated that dendrimers were 
not toxic, since no significant differences were observed in 
survival rates of peptide- or Tob-administrated larvae, as 
indicated by the log-rank (Mantel–Cox) test. In accordance 
with our findings, Stach et al19 found that dG3KL combined 
good broad-spectrum activity with >200-fold selectivity 
against hemolysis.
The development of new antimicrobial agents requires 
confirmation of their efficacy in vivo. In this context, it 
was recently found that TNS18 shows promising activity 
in a murine infection model with MDR clinical isolates of 
A.  baumannii and Escherichia coli, providing the first evidence 
that AMPs might be amenable to in vivo use.20 In spite of their 
good in vitro antibacterial activity and lack of in vivo toxicity, 
neither dendrimer was able to protect G. mellonella larvae 
against systemic infection caused by P. aeruginosa. Tob showed 
a protective effect against P. aeruginosa infection compared to 
untreated larvae, regardless of the strain tested. The inability of 
peptides to provide protection against P. aeruginosa infection 
might be explained by the scarce stability of the peptides in 
G. mellonella, since they were inactive already within 4 hours 
posttreatment, as suggested by kinetic results of bacterial 
growth in hemolymph. Peptide inactivation is probably not due 
to degradation by host or bacterial proteases, since both dG3KL 
and dTNS18 contain only d-amino acids. Confirming the sta-
bility of dG3KL, Stach et al recently reported that contrarily 
to its precursor G3KL, it is not degraded in the presence of 
human serum.19 Numerous other factors could be responsible 
for the lack of pronounced activity following therapy with 
dendrimers, including the virulence of the strains used and/
or the in vivo distribution and bioavailability of the peptide.
Conclusion
The results from the present study indicate for the first time 
that dG3KL and dTNS18 peptide dendrimers have good in 
vitro activity against both P. aeruginosa planktonic and bio-
film cells at concentrations not toxic in vivo. Despite these 
promising results, the lack of protective effect observed in 
G. mellonella larvae suggests that these peptides have some 
pharmacokinetic limitations that need to be identified and 
eliminated in order to improve their effectiveness. Further 
studies are warranted to explore different dosages and to 
increase the bioavailability of the peptides. Finally, it is 
worth considering that the rapid synthesis and use of standard 
amino acids only (especially in the case of dTNS18, only half 
the size of dG3KL), as well as the slow resistance develop-
ment,19 present further significant advantages for the potential 
development of AMPs as a new class of antimicrobial agents.
Abbreviation list
AMPs, antimicrobial peptides
CAMHB, cation-adjusted Mueller–Hinton broth
CF, cystic fibrosis
DCM, dichloromethane
DIC, N,N’-diisopropyl carbodiimide
DMF, N,N-dimethylformamide
MBC, minimum bactericidal concentration
MDR, multidrug-resistant
MHA, Mueller–Hinton agar
MIC, minimum inhibitory concentration
MRSA, methicillin-resistant Staphylococcus aureus
TFA, trifluoroacetic acid
TSB, trypticase soy broth
tBME, tert-butyl methyl ether
Tob, tobramycin
PE, postexposure
LD
50
, lethal dose 50
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